First Patients Reach 12-Month Endpoint in Pivotal Trial for Envoy Medical's Fully Implanted Cochlear Implant
Summary
Envoy Medical announced that the first three patients in its pivotal clinical trial for the fully implanted Acclaim cochlear implant have successfully completed their 12-month endpoint visit. This is a critical milestone as the primary endpoints for the trial are tied to 12-month data, and its achievement keeps the company on schedule for its Premarket Approval (PMA) submission to the FDA. This positive development provides a much-needed boost for the micro-cap company, which has recently disclosed a going concern warning, a highly dilutive offering, a Nasdaq delisting threat, and an auditor change. Successful completion of the trial and subsequent FDA approval are crucial for the company's long-term viability and commercialization efforts.
At the time of this announcement, COCH was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.1M. The 52-week trading range was $0.36 to $1.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.